What Is Afatinib (Giotrif)? FDA Approval, Authorization and Reimbursement Status in Turkey
In this article
Irreversible Blockade in Lung Cancer: Afatinib
Used in metastatic non-small cell lung cancer (NSCLC), Afatinib (Giotrif®)is a potent targeted agent that irreversibly blocks receptors and stops tumor growth, particularly in EGFR mutation-positive patients.
Drug Profile
- Brand Name: Giotrif®
- Active Ingredient: Afatinib
- Class: Signal Transduction Inhibitor, Pan-ErbB (EGFR/HER) Inhibitor
- Route of Administration: Oral (Tablet)
- Manufacturer: Boehringer Ingelheim
- Authorization: Authorized in Turkey. Initial authorization: 31.10.2016
- Reimbursement: Included on the SGK reimbursement list.
-
Therapeutic Indications
Afatinib is indicated until progression as first-line treatment, or second-line treatment after progression following one line of chemotherapy, in locally advanced or metastatic non-small cell lung cancer with an epidermal growth factor receptor (EGFR) exon 19 deletion and/or exon 21 (L858R) mutation confirmed by an accredited laboratory. These patients must not previously have received tyrosine kinase inhibitors (TKIs) targeting these alterations.
- March 2026 Price: Per 1 pack of 20/30/40 mg tablets: 49615.18 TL.
Approved Indications
- Metastatic NSCLC: First-line treatment for patients with EGFR exon 19 deletions or exon 21 (L858R) mutations.
- Uncommon EGFR Mutations: Patients carrying S768I, L861Q or G719X mutations.
- Squamous NSCLC: Metastatic disease progressing after platinum-based chemotherapy.
FDA Approval History
First-line approval for metastatic NSCLC with EGFR exon 19 deletions or exon 21 mutations.
Expanded approval for squamous lung cancer progressing after chemotherapy.
Approval covering uncommon mutations such as S768I, L861Q and G719X.
What Is Afatinib and How Does It Work at the Molecular Level?
Afatinib targets the ErbB receptor family (EGFR, HER2, HER4) as an irreversible tyrosine kinase inhibitor. Unlike other TKIs, it binds covalently to its target and permanently shuts down signaling.
🔬 How It Works at the Molecular Level
- 1. Irreversible Blockade:
Afatinib attaches covalently to the receptor's tyrosine kinase domain. This bond does not break, so signaling stops until the cell synthesizes new receptors. - 2. Pan-ErbB Inhibition:
It blocks not only EGFR (ErbB1), but also HER2 (ErbB2) and HER4, preventing backup signaling and escape mechanisms. - 3. Mutation-Specific Activity:
It targets mutant receptors driving uncontrolled proliferation, including exon 19, 21 and certain uncommon mutations, with high affinity. - 4. Interruption of Signaling Pathways:
It shuts down vital intracellular growth and survival pathways, such as RAS-RAF-MEK-ERK and PI3K-AKT-mTOR, at their upstream entry point.
Administration and Dosage
Afatinib is taken as a daily oral tablet.
- Recommended Dose: 40 mg in 1 daily dose.
- Fasting Rule: Take at least 1 hour before or 3 hours after food (food affects absorption).
- Dose Adjustment: To manage side effects, a physician may reduce the dose to 30 mg or 20 mg.
Resistance Mechanisms
During treatment, cancer cells may develop new strategies to survive:
| Mechanism | Description |
|---|---|
| ErbB Mutations | Receptor structural changes physically prevent drug binding. |
| Genetic Mutations | KRAS and BRAF mutations may weaken effectiveness. |
| Alternative Pathways | Activation of other signaling pathways, such as c-Met or mTORC1. |
Side Effects and Management
The most common adverse effects arise from tissue effects of EGFR inhibition:
- Diarrhea: The most frequent side effect (85-95%). Early treatment with drugs such as loperamide is important.
- Skin Reactions: Acne-like rash (90%), itching and dryness. Sun protection and topical antibiotics are recommended.
- Mucositis: Mouth sores and irritation (5-10%).
- Nail Changes: Paronychia (nail-bed inflammation) (15-25%).
- Uncommon but Serious: Interstitial lung disease (1.5%) and liver toxicity.
Special Situations and Warnings
- Food Interactions: Avoid grapefruit, pomelo, Seville oranges and star fruit (may increase drug levels).
- Pregnancy (Category D): Do not use during pregnancy or breastfeeding. Effective contraception is essential.
- Eye Health: Contact lens wearers should be monitored for keratitis.
- Elimination: Mostly (85%) eliminated in feces; dose adjustment is generally unnecessary in renal impairment.
Pharmacokinetic Summary
- Bioavailability: Approximately 92%.
- Half-Life: Approximately 37 hours.
- Metabolism: Occurs through hepatic CYP3A4 enzymes. Interactions may occur with CYP inducers, such as rifampin, or inhibitors, such as erythromycin.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.